We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > iptacopan

News List

Novartis' oral therapy iptacopan shows promise in PNH pharmatimes
June 16, 2021
Novartis has revealed new positive data for its investigational treatment iptacopan as a monotherapy treatment for patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH).
Novartis Announces Iptacopan Met Primary Endpoint in Rare Kidney Disease IgA Nephropathy americanpharmaceuticalreview
June 09, 2021
Novartis announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, oral, targeted factor B inhibitor – reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating ...
Novartis’ rare renal disease candidate shows promise in phase II pharmatimes
October 29, 2020
Interim analysis results for Novartis’ rare renal disease candidate iptacopan proved promising in a phase II study of the investigational drug.